Nurix Therapeutics (NRIX) said Monday that the US Food and Drug Administration has granted orphan drug designation to the company's experimental drug, bexobrutideq, for treating Waldenstrom macroglobulinemia, a type of blood cancer.
The company said the drug is currently being evaluated in a phase 1 trial for adults with relapsed or refractory B-cell malignancies.
The US health agency's orphan drug designation program supports the development of treatments for rare diseases, impacting fewer than 200,000 individuals in the US, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。